Compare RELL & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | ORGO |
|---|---|---|
| Founded | 1947 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 299.8M |
| IPO Year | 2004 | 2016 |
| Metric | RELL | ORGO |
|---|---|---|
| Price | $17.49 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 157.0K | ★ 705.2K |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | $208,909,000.00 | ★ $564,169,000.00 |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $7.91 | $26.27 |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $9.37 | $2.04 |
| 52 Week High | $19.86 | $7.08 |
| Indicator | RELL | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 46.89 |
| Support Level | $10.17 | $2.26 |
| Resistance Level | $19.40 | $2.58 |
| Average True Range (ATR) | 1.03 | 0.12 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 53.75 | 35.09 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.